What is the role of combination figitumumab, paclitaxel and carboplatin in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

In a phase II trial, Karp et al studied the effect of the anti-insulin-like growth factor 1 receptor antibody CP-751,871 (figitumumab) combined with paclitaxel and carboplatin in advanced treatment-naive NSCLC. Patients were randomized (2:1) to receive paclitaxel 200 mg/m2, carboplatin (area under the concentration-time curve [AUC] of 6), and CP-751,871 at a dose of 10 or 20 mg/kg (PCI[10] or PCI [20]); or paclitaxel and carboplatin alone (PC) every 3 weeks for up to 6 cycles. The PCI(20)/PC hazard ratio for progression-free survival was 0.8-0.56, indicating safety and efficacy in NSCLC. A randomized, open-label, phase III trial is currently under way. [201]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!